Next Steps in the CAR Journey of a Thousand Miles.
作者信息
Brenner Malcolm K
机构信息
Center for Cell and Gene Therapy at Baylor College of Medicine, Houston Methodist Hospital, and Texas Children's Hospital, Houston, TX 77030, USA.
出版信息
Mol Ther. 2017 Oct 4;25(10):2226-2227. doi: 10.1016/j.ymthe.2017.09.013. Epub 2017 Sep 20.
Abstract
摘要
相似文献
1
Next Steps in the CAR Journey of a Thousand Miles.
Mol Ther. 2017 Oct 4;25(10):2226-2227. doi: 10.1016/j.ymthe.2017.09.013. Epub 2017 Sep 20.
2
Advances in off-the-shelf CAR T-cell therapy.
Clin Adv Hematol Oncol. 2019 Mar;17(3):155-157.
3
Serving "a la CAR-T": Value-Based Pricing and Gene Therapy.
J Natl Compr Canc Netw. 2017 Oct;15(10):1179. doi: 10.6004/jnccn.2017.0162.
4
CAR-T Cells for Cancer Treatment: Current Design and Next Frontiers.
Methods Mol Biol. 2020;2086:1-10. doi: 10.1007/978-1-0716-0146-4_1.
5
Chimeric antigen receptor T cell therapy: 25years in the making.
Blood Rev. 2016 May;30(3):157-67. doi: 10.1016/j.blre.2015.10.003. Epub 2015 Nov 6.
6
CAR T-cell therapy against B-cell maturation antigen in multiple myeloma.
Clin Adv Hematol Oncol. 2018 Dec;16(12):804-806.
7
Prospects for chimeric antigen receptor-modified T cell therapy for solid tumors.
Mol Cancer. 2018 Jan 12;17(1):7. doi: 10.1186/s12943-018-0759-3.
8
CAR T-cell therapy: Full speed ahead.
Hematol Oncol. 2019 Jun;37 Suppl 1:95-100. doi: 10.1002/hon.2591.
9
Next-generation CAR T cells to overcome current drawbacks.
Int J Hematol. 2021 Nov;114(5):532-543. doi: 10.1007/s12185-020-02923-9. Epub 2020 Jun 27.
10
Of chimeric antigen receptors and antibodies: OX40 and 41BB costimulation sharpen up T cell-based immunotherapy of cancer.
Immunotherapy. 2013 Jul;5(7):677-81. doi: 10.2217/imt.13.54.
引用本文的文献
1
Epigenetic Inhibition Puts Target Antigen in the Crosshairs of CAR T Cells.
Mol Ther. 2019 May 8;27(5):900-901. doi: 10.1016/j.ymthe.2019.04.007. Epub 2019 Apr 18.
2
Overcoming Target Driven Fratricide for T Cell Therapy.
Front Immunol. 2018 Dec 12;9:2940. doi: 10.3389/fimmu.2018.02940. eCollection 2018.
3
Seek and You Will Not Find: Ending the Hunt for Replication-Competent Retroviruses during Human Gene Therapy.
Mol Ther. 2018 Jan 3;26(1):1-2. doi: 10.1016/j.ymthe.2017.12.004. Epub 2017 Dec 20.
本文引用的文献
1
Chimeric antigen receptor T cells for sustained remissions in leukemia.
N Engl J Med. 2014 Oct 16;371(16):1507-17. doi: 10.1056/NEJMoa1407222.
2
T-cell immunotherapy: looking forward.
Mol Ther. 2014 Sep;22(9):1564-74. doi: 10.1038/mt.2014.148.
3
CARs on track in the clinic.
Mol Ther. 2011 Mar;19(3):432-8. doi: 10.1038/mt.2011.1.
4
Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding domains and the gamma or zeta subunits of the immunoglobulin and T-cell receptors.
Proc Natl Acad Sci U S A. 1993 Jan 15;90(2):720-4. doi: 10.1073/pnas.90.2.720.
5
Infusions of donor leukocytes to treat Epstein-Barr virus-associated lymphoproliferative disorders after allogeneic bone marrow transplantation.
N Engl J Med. 1994 Apr 28;330(17):1185-91. doi: 10.1056/NEJM199404283301703.
6
Use of gene-modified virus-specific T lymphocytes to control Epstein-Barr-virus-related lymphoproliferation.
Lancet. 1995 Jan 7;345(8941):9-13. doi: 10.1016/s0140-6736(95)91150-2.
7
Graft-versus-leukemia reactions after bone marrow transplantation.
Blood. 1990 Feb 1;75(3):555-62.
8
Donor leukocyte transfusions for treatment of recurrent chronic myelogenous leukemia in marrow transplant patients.
Blood. 1990 Dec 15;76(12):2462-5.
Zotero 插件